Doripenem Dosing, Clinical Uses, and Discontinuation
Direct Answer
Doripenem was discontinued from the U.S. market in 2014 by the manufacturer (Janssen) due to commercial reasons, not safety concerns, though a clinical trial showing increased mortality with prolonged infusion in ventilator-associated pneumonia contributed to its limited adoption.
Approved Doses and Clinical Indications
Standard Dosing Regimens
Doripenem was FDA-approved at 500 mg IV every 8 hours as a 1-hour infusion for two specific indications: 1
- Complicated intra-abdominal infections - 500 mg IV every 8 hours
- Complicated urinary tract infections - 500 mg IV every 8 hours
Extended Infusion Strategies
For enhanced pharmacodynamic optimization, 4-hour infusions were studied to maximize time above MIC (fT>MIC), particularly for resistant organisms: 1, 2
- 1,000 mg every 8 hours as 4-hour infusion for patients with CrCl 30-100 mL/min targeting pathogens with MIC ≤8 mg/L 2
- 2,000 mg every 8 hours as 4-hour infusion for patients with CrCl >100 mL/min 2
Special Population Dosing
Renal impairment: Dosing must be adjusted based on creatinine clearance, as doripenem clearance is significantly influenced by renal function 2
Hemodialysis patients: 1 g post-hemodialysis dosing achieves adequate plasma levels in anuric patients, though interpatient variability is considerable 3
Pediatric patients (<12 weeks):
Obese patients (BMI ≥40 kg/m²): Standard 500 mg every 8 hours achieves adequate 40% fT>MIC, but prolonged infusions of larger doses (1-2 g) needed for 100% fT>MIC targets 5
CRRT patients: Continuous infusion of 2.5 mg/kg/hr (60 mg/kg/day) with therapeutic drug monitoring, as clearance is significantly increased during CRRT 6
Antimicrobial Spectrum
Doripenem's spectrum closely resembles meropenem and imipenem, with notable activity against: 1
- Streptococci and methicillin-susceptible staphylococci
- Enterobacteriaceae (including ESBL-producing strains)
- Pseudomonas aeruginosa (with potentially enhanced activity compared to other carbapenems)
- Acinetobacter species
- Bacteroides fragilis
Critical gaps in coverage: No clinically useful activity against MRSA, VRE, or carbapenem-resistant Gram-negative bacilli 1
Guideline Recommendations (Pre-Discontinuation)
Intra-Abdominal Infections
For high-risk or severely ill adults with intra-abdominal infections, doripenem was listed alongside imipenem, meropenem, and piperacillin-tazobactam as appropriate empiric therapy 7
For hospital-acquired infections in critically ill patients, doripenem was recommended as an alternative carbapenem option 7
Carbapenem-Resistant Pseudomonas
In patients with carbapenem-resistant P. aeruginosa intermediately susceptible to doripenem (MIC 4-8 mg/L), high-dose 4-hour infusions combined with fosfomycin showed comparable outcomes to colistin-based regimens 8
Why Doripenem Was Discontinued
Primary Reason: Commercial Decision
The manufacturer voluntarily withdrew doripenem from the U.S. market in 2014 for commercial reasons, not due to FDA-mandated safety concerns 9
Contributing Clinical Factor: ATTAIN Trial
A pivotal clinical trial in ventilator-associated pneumonia showed increased mortality with doripenem 1 g every 8 hours as 4-hour infusion compared to imipenem, which significantly impacted its clinical adoption and commercial viability 1
Market Competition
Doripenem offered no clear clinical advantages over the already-established meropenem, while being more expensive, limiting its market penetration 9
Current Status
The drug remains approved in some international markets but is not commercially available in the United States. When guidelines reference doripenem, they now typically recommend meropenem as the preferred carbapenem alternative 7
Safety Profile
Common adverse effects included: 9
- Headache
- Nausea and diarrhea
- Rash
- Phlebitis at injection site
Serious but rare: Seizure risk exists as with all carbapenems, though doripenem demonstrated lower propensity for seizures in vitro and clinical studies 1
Clinical Pearls
Doripenem demonstrated harder-to-select resistant P. aeruginosa mutants in vitro compared to other carbapenems, with approximately 29% of carbapenem-resistant P. aeruginosa isolates remaining sensitive 9, though the clinical relevance of this finding was never fully established before discontinuation.